For the patients in the combination regimen, the mean of the total intervention cost per patient was $5,508, compared to $7,381 for the patients in G-CSF regimen. The significant reduction in costs in the combination regimen was due to the reduction of costly procedures, cryopreservation and leukapheresis in this case, made possible by the collection of larger number of progenitor cells during apheresis. This saving in costs was enough to overcome the complication costs of one case of febrile neutropenia observed in this cohort of patients.